Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-04

Clinical Trial Update: Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pasireotide in patients with acromegaly inadequately controlled by first-generation somatostatin analogues has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pasireotide (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly | Phase 3 | Status: COMPLETED | Results posted: 2019-12-04